Watchful Waiting Unsuitable in Black Prostate Cancer Patients

Share this content:
Black watchful waiting patients more likely to develop aggressive disease earlier.
Black watchful waiting patients more likely to develop aggressive disease earlier.

Watchful waiting may not be suitable for all men with early-stage prostate cancer, especially black patients, according to research published in Urologic Oncology.

The researchers analyzed the medical records of men who were confirmed to have low-grade prostate cancer and had surgery to remove part or all of the prostate.

Among these patients, blacks were more likely than whites to have cancer progression and worse outcomes. Seven years after surgery, rates of disease control were 90 percent among whites and 79 percent among blacks.

RELATED: Physicians Rarely Recommend 'Watchful Waiting' for Men with Low-Risk Prostate Cancer

"We know that African-American men have more aggressive prostate cancer than Caucasian men," Kosj Yamoah, M.D., Ph.D., chief resident in the department of radiation oncology at Thomas Jefferson University in Philadelphia, said in a university news release.

"Our study shows that African-American men who are diagnosed with a low-grade cancer at first -- the cancers that are sometimes watched rather than treated -- are more likely to develop aggressive disease sooner than Caucasian men," he said.

Reference

  1. "Watchful Waiting Isn't Right for Everyone." Thomas Jefferson University. September 9, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs